Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in episodic migraine prevention
NCT05217927Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 4, randomised, double-blind trial of rimegepant in migraine (3 arms), sponsored by Pfizer. Primary endpoint: Mean Change From Observation Phase in the Number of Migraine Days Per Month Over Entire DBT Phase at 12 weeks. Started Mar 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05217927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217927.